Talphera, Inc. (NASDAQ:TLPH) Short Interest Down 18.9% in October

Talphera, Inc. (NASDAQ:TLPH) was the target of a large drop in short interest in October. As of October 15th, there was short interest totalling 34,300 shares, a drop of 18.9% from the September 30th total of 42,300 shares. Based on an average trading volume of 95,400 shares, the short-interest ratio is presently 0.4 days. Approximately 0.2% of the shares of the company are short sold.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Talphera stock. Nantahala Capital Management LLC acquired a new stake in shares of Talphera, Inc. (NASDAQ:TLPH) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,992,519 shares of the company’s stock, valued at approximately $1,773,000. Nantahala Capital Management LLC owned 11.73% of Talphera at the end of the most recent quarter. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Talphera Stock Down 4.0 %

Shares of NASDAQ TLPH opened at $0.96 on Wednesday. The business’s 50 day moving average is $0.91 and its two-hundred day moving average is $0.95. The company has a market cap of $16.31 million, a P/E ratio of -1.08 and a beta of 0.32. Talphera has a 12 month low of $0.43 and a 12 month high of $1.61.

Talphera (NASDAQ:TLPH) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.07. Sell-side analysts expect that Talphera will post -0.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Talphera in a research note on Friday, August 16th.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.